CERT Technologies

CERT Technologies is a biotechnology company focused on developing novel therapeutics that target the Ceramide Transfer Protein (CERT), a key regulator of lipid metabolism and cell signaling. By inhibiting CERT, the company aims to disrupt the transport of ceramide from the endoplasmic reticulum to the Golgi apparatus, thereby inducing apoptosis in cancer cells and overcoming drug resistance. Their research primarily targets various solid tumors, including breast, colorectal, and ovarian cancers, where CERT is often overexpressed. The company's lead programs involve small molecule inhibitors designed to sensitize tumors to existing chemotherapeutic agents and provide new options for difficult-to-treat malignancies.